Ligand Pharmaceuticals LGND Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's operating lease liabilities (current)?
- Ligand Pharmaceuticals (LGND) reported operating lease liabilities (current) of $1.09M in Q1 2026.
- How has Ligand Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Ligand Pharmaceuticals's operating lease liabilities (current) increased by 26.7% year-over-year, from $859K to $1.09M.
- What is the long-term trend for Ligand Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's operating lease liabilities (current) has grown at a -10.3% compound annual growth rate (CAGR), from $1.89M to $1.1M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.